TW200738719A - Organic compounds - Google Patents

Organic compounds

Info

Publication number
TW200738719A
TW200738719A TW096102341A TW96102341A TW200738719A TW 200738719 A TW200738719 A TW 200738719A TW 096102341 A TW096102341 A TW 096102341A TW 96102341 A TW96102341 A TW 96102341A TW 200738719 A TW200738719 A TW 200738719A
Authority
TW
Taiwan
Prior art keywords
phenyl
ethyl
piperazin
pyrrolo
pyrimidin
Prior art date
Application number
TW096102341A
Other languages
Chinese (zh)
Inventor
Michael Mutz
Reto Fischer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37946476&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200738719(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TW200738719A publication Critical patent/TW200738719A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The invention relates to new crystalline forms of{6-[4-(4-ethyl-piperazin-1-ylmethyl)-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}-((R)-1-phenyl-ethyl)-amine, the process for the preparation of these crystalline forms of {6-[4-(4-ethyl-piperazin-1-ylmethyl)-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}-((R)-1-phenyl-ethyl)-amine, compositions containing these crystalline forms of {6-[4-(4-ethyl-piperazin-1-ylmethyl)-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}-((R)-1-phenyl-ethyl)-amine, and the use of these crystalline forms of {6-[4-(4-ethyl-piperazin-1-ylmethyl)-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}-((R)-1-phenyl-ethyl)-amine in diagnostic methods or therapeutic treatment of warm-blooded animals, especially humans.
TW096102341A 2006-01-23 2007-01-22 Organic compounds TW200738719A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US76122406P 2006-01-23 2006-01-23

Publications (1)

Publication Number Publication Date
TW200738719A true TW200738719A (en) 2007-10-16

Family

ID=37946476

Family Applications (1)

Application Number Title Priority Date Filing Date
TW096102341A TW200738719A (en) 2006-01-23 2007-01-22 Organic compounds

Country Status (13)

Country Link
EP (1) EP1979357A1 (en)
JP (1) JP2009523768A (en)
KR (1) KR20080095859A (en)
CN (1) CN101370814A (en)
AR (1) AR059090A1 (en)
AU (1) AU2007206925A1 (en)
BR (1) BRPI0706729A2 (en)
CA (1) CA2636954A1 (en)
PE (1) PE20071323A1 (en)
RU (1) RU2008134314A (en)
TN (1) TNSN08312A1 (en)
TW (1) TW200738719A (en)
WO (1) WO2007082946A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20011349A1 (en) * 2000-06-16 2002-01-19 Upjohn Co 1-ARIL-4-OXO-1,4-DIHYDRO-3-QUINOLINE CARBOXAMIDES AS ANTIVIRAL AGENTS
GB0119249D0 (en) * 2001-08-07 2001-10-03 Novartis Ag Organic compounds
EP1441736A2 (en) * 2001-10-29 2004-08-04 Novartis AG Use of 7h-pyrrolo[2,3-d]pyrimidine derivatives in the treatment of solid tumor diseases
US20080227980A1 (en) * 2005-08-05 2008-09-18 Novartis Ag Preparation of a 7H-Pyrrolo [2,3-D] Pyrimidine Derivative

Also Published As

Publication number Publication date
AR059090A1 (en) 2008-03-12
RU2008134314A (en) 2010-02-27
WO2007082946A1 (en) 2007-07-26
BRPI0706729A2 (en) 2011-04-05
AU2007206925A1 (en) 2007-07-26
PE20071323A1 (en) 2008-02-15
KR20080095859A (en) 2008-10-29
TNSN08312A1 (en) 2009-12-29
CN101370814A (en) 2009-02-18
JP2009523768A (en) 2009-06-25
CA2636954A1 (en) 2007-07-26
EP1979357A1 (en) 2008-10-15

Similar Documents

Publication Publication Date Title
MX2009006700A (en) 5-cyan0-4- (pyrrolo [2, 3b] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors.
WO2007120752A3 (en) 4, 5-dihydro- [1, 2, 4] triazolo [4, 3-f] pteridines as protein kinase plk1 inhibitors for the treatment of proliferative disorders
HK1113569A1 (en) Pyrazolo
MX2010006748A (en) PYRAZOLO [1,5-a] PYRIMIDINES USEFUL AS JAK2 INHIBITORS.
WO2009087225A3 (en) Pyrrolopyrimidines and pyrrolopyridines
TW200633980A (en) Pyridones useful as inhibitors of kinases
MX2009009592A (en) Aminopyridines useful as inhibitors of protein kinases.
WO2007095223A3 (en) Pyrrolo(3,2-c) pyridines useful as inhibitors of protein kinases
TW200613305A (en) Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
MX2009008253A (en) Kinase inhibitors.
MY150059A (en) Pyrrolo [2,3-d] pyrimidin derivatives as protein kinase b inhibitors
WO2010011772A3 (en) Tri-cyclic pyrazolopyridine kinase inhibitors
TNSN07165A1 (en) Organic compounds
HK1116349A1 (en) Pyrrolopyrimidines useful as inhibitors of protein kinase
WO2008121687A3 (en) Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
WO2007022384A3 (en) Pyrazine kinase inhibitors
WO2007015923A8 (en) Benzimidazoles useful as inhibitors of protein kinases
MX2009006345A (en) Compounds useful as protein kinase inhibitors.
WO2008070313A3 (en) 3-(dihydro-1h-pyrazolo [4,3-d] pyrimidin-5-yl)-4-propoxybenzenesulfonamide derivatives and methods of use
WO2007120760A3 (en) Thiophene-carboxamides useful as inhibitors of protein kinases
MY150747A (en) Pyrido[2,3-d] pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
TW200726770A (en) Organic compounds
NO20080418L (en) Pyrido [2,3-D] pyrimidiride derivatives, process for their preparation and therapeutic use of the same
PT1869038E (en) Substituted 5,6,7,8-tetrahydro-imidazo[1,2-a]pyridin-2-ylamine compounds and their use for producing drugs
MX2009005231A (en) Compounds useful as protein kinase inhibitors.